Advisory Services Network’s Karyopharm Therapeutics KPTI Stock Holding History

Advisory Services Network’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12	Closed	-$67	–	3520
2026 Q1	$67	Buy	+12	New	+$91	﹤0.01%	4733
2025 Q4	–	Sell	-12	Closed	-$78	–	3167
2025 Q3	$78	Buy	+12	New	+$65	﹤0.01%	4407
2024 Q1	–	Sell	-33	Closed	-$433	–	2654
2023 Q4	$433	Buy	+33	New	+$445	﹤0.01%	3639
2023 Q2	–	Sell	-40	Closed	-$2.33K	–	2634
2023 Q1	$2.33K	Hold	40	–	–	﹤0.01%	3397
2022 Q4	$2.04K	Buy	+40	New	+$2.77K	﹤0.01%	3425
2021 Q3	–	Sell	-60	Closed	-$9K	–	2403
2021 Q2	$9K	Buy	+60	New	+$8.71K	﹤0.01%	2852
2021 Q1	–	Sell	-60	Closed	-$14K	–	2213
2020 Q4	$14K	Hold	60	–	–	﹤0.01%	2279
2020 Q3	$13K	Buy	+60	New	+$14.7K	﹤0.01%	2283

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisory Services Network's KPTI Position: Q2 2026 in Review

Advisory Services Network sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 12 shares — an estimated $67 sold.

Advisory Services Network first reported a position in KPTI in Q3 2020 and held it in 8 quarters. The position peaked at $14K in Q4 2020. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Advisory Services Network reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 12 Karyopharm Therapeutics shares in Q2 2026, an estimated $67.
Advisory Services Network first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 8 quarters.
Advisory Services Network's Karyopharm Therapeutics position peaked at $14K in Q4 2020.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.